NeuroSense Therapeutics Ltd(NRSN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 7:30 PM ET (Korea 10/1 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 34.02% | Shs Outstand | 1.9M | Perf Week | -40.14% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -55.77% | Insider Trans | 344.72% | Shs Float | 1.3M | Perf Month | -48.09% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 1.05% | Short Float | 3.06% | Perf Quarter | -69.36% |
| Income | - | P/S | - | EPS this Y | 24.81% | Inst Trans | - | Short Ratio | 1.99 | Perf Half Y | -70.66% |
| Sales | - | P/B | - | EPS next 5Y | 4.85% | ROA | - | Short Interest | 0.04M | Perf YTD | -71.2% |
| Book/sh | - | P/C | - | EPS past 3/5Y | 25.89% 21.42% | ROE | - | 52W High | -83.37% ($26.64) | Perf Year | -82.28% |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 1.72% ($4.36) | Perf 3Y | -68.8% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 31.09% | Gross Margin | - | Volatility(W/M) | 18.94% 18.3% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | 59.58% | Profit Margin | - | RSI (14) | 29.06 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | -36.61% ($6.99) | Beta | 1.62 | Target Price | $97.33 |
| Payout | - | Debt/Eq | - | Earnings | 2026/09/02 | SMA50 | -47.58% ($8.45) | Rel Volume | 2.1 | Prev Close | $4.78 |
| Employees | 16 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -69.33% ($14.44) | Avg Volume(3M) | 0.02M | Price | $4.43 |
| IPO | 2021/12/9 | Option/Short | No/Yes | Trades | 9506 | Volume | 40,263 | Change | -7.32% |
🧠 NeuSense Therapeutics () is an Israel-based clinical-stage biotech developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's. Its lead candidate, PrimeC, is an extended-release oral combination of two FDA-approved drugs (ciprofloxacin and celecoxib), and in November 2025 it received FDA clearance to begin a Phase 3 trial (the PARAGON study).
Over the past 1 year, on the lower side
83% below its 1-year high.
Traded more than usual That is 210% of its average volume.
Growth has stalled
Earnings are expected to grow by +24.8% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -68.8%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.1%.
Tap to view numbers
It ranks #522 of 592 in the industry
Based on market cap of $8M.
LGVN#521 Longeveron Inc $9M PER - NRSN#522 NeuroSense Therapeutics Ltd $8M PER - 
ALZN#523 Alzamend Neuro Inc $8M PER - 
AZTR#524 Azitra Inc $8M PER - 
KALA#525 Kala Bio Inc $8M PER - 
FAQ
What kind of company is NRSN?
NRSN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NRSN?
The market cap of NRSN is approximately $8M, ranking 5,541 within its sector.
What is the 52-week high and low for NRSN?
NRSN has recorded a 52-week high of $26.64 and a low of $4.36.
